Free Trial

Landos Biopharma (LABP) Stock Price, News & Analysis

+0.13 (+0.57%)
(As of 05/23/2024)
Today's Range
50-Day Range
52-Week Range
50,800 shs
Average Volume
19,700 shs
Market Capitalization
$71.77 million
P/E Ratio
Dividend Yield
Price Target

Landos Biopharma MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
10.9% Downside
$20.42 Price Target
Short Interest
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($2.19) to ($1.68) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.02 out of 5 stars

Medical Sector

889th out of 892 stocks

Pharmaceutical Preparations Industry

423rd out of 424 stocks

LABP stock logo

About Landos Biopharma Stock (NASDAQ:LABP)

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

LABP Stock Price History

LABP Stock News Headlines

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Leerink Partners Remains a Hold on Landos Biopharma (LABP)
AbbVie To Acquire Landos Biopharma At $20.42/share In Cash
AbbVie to buy Landos Biopharma for $137 million
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
Recap: Landos Biopharma Q4 Earnings
Xontogeny, LLC's Net Worth
See More Headlines
Receive LABP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Landos Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$18 million
Book Value
$7.41 per share


Free Float
Market Cap
$71.77 million
Not Optionable
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

LABP Stock Analysis - Frequently Asked Questions

Should I buy or sell Landos Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Landos Biopharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" LABP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LABP, but not buy additional shares or sell existing shares.
View LABP analyst ratings
or view top-rated stocks.

What is Landos Biopharma's stock price target for 2024?

1 analysts have issued 1 year target prices for Landos Biopharma's shares. Their LABP share price targets range from $20.42 to $20.42. On average, they expect the company's stock price to reach $20.42 in the next twelve months. This suggests that the stock has a possible downside of 10.9%.
View analysts price targets for LABP
or view top-rated stocks among Wall Street analysts.

How have LABP shares performed in 2024?

Landos Biopharma's stock was trading at $3.66 at the beginning of 2024. Since then, LABP stock has increased by 526.5% and is now trading at $22.93.
View the best growth stocks for 2024 here

When is Landos Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our LABP earnings forecast

How were Landos Biopharma's earnings last quarter?

Landos Biopharma, Inc. (NASDAQ:LABP) issued its earnings results on Thursday, May, 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.00) by $0.43.

When did Landos Biopharma's stock split?

Landos Biopharma's stock reverse split before market open on Friday, May 26th 2023. The 1-10 reverse split was announced on Friday, May 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Landos Biopharma IPO?

Landos Biopharma (LABP) raised $101 million in an IPO on Thursday, February 4th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Raymond James was co-manager.

Who are Landos Biopharma's major shareholders?

Landos Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Deltec Asset Management LLC (1.60%), Virtu Financial LLC (0.46%) and Black Maple Capital Management LP (0.33%). Insiders that own company stock include Josep Bassaganya-Riera and Rtw Investments, Lp.
View institutional ownership trends

How do I buy shares of Landos Biopharma?

Shares of LABP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LABP) was last updated on 6/23/2024 by Staff

From Our Partners